NCT02090725View on ClinicalTrials.gov

Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS)

PHASE2TerminatedINTERVENTIONAL

Enrollment

4

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

July 31, 2018

Study Completion Date

November 28, 2018

Conditions

Muscle Weakness

Interventions

DRUG

3-4 Diaminopyridine

Trial Locations (1)

03221

Dartmouth-Hitchcock Medical Center, Lebanon

Sponsors

Collaborators (1)

Jacobus Pharmaceutical

All Listed Sponsors

collaborator

Jacobus Pharmaceutical

INDUSTRY

lead

Jeffrey A. Cohen, MD

OTHER